Business
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype - WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced recent positive preclinical results from its potent and selective ITK/JAK3 inhibitor ATI-2138 in a murine model of severe alopecia areata (AA). In this model of
About this update from Aclaris Therapeutics, Inc.
[{"type":"image","alt":"Aclaris Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Aclaris Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":126,"url":"https://media.zenfs.com/en/globenewswire.com/863f11ac89f9dbe84886691262d6e9f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6F15OlckspEeRRnvMP1sTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/863f11ac89f9dbe84886691262d6e9f8","width":300,"height":126}},"lazy":false},{"type":"text","content":"- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype -","length":109,"tagName":"p"},{"type":"text","content":"WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced recent positive preclinical results from its potent and selective ITK/JAK3 inhibitor ATI-2138 in a murine model of severe alopecia areata (AA). In this model of hair loss, conducted by Dr. Angela Christiano at Columbia University, ATI-2138 demonstrated rapid, near complete, and sustained hair regrowth compared to control and ritlecitinib.","length":569,"tagName":"p"},{"type":"text","content":"“ATI-2138 is a potent and selective inhibitor of ITK and JAK3 with dual pharmacology that has been demonstrated to downregulate Th1, Th2, Th17, TCR (ITK) and fibrosis pathway markers, and reduce itch; this makes it an excellent mechanistic fit in a variety of I&I diseases, including across the spectrum of inflammatory alopecias,” said Dr. Roland Kolbeck, Chief Scientific Officer of Aclaris. “The mice used in this model of severe alopecia areata were significantly older and more difficult to treat than those typically studied; despite that, ATI-2138 induced an accelerated response and near complete regrowth after only four weeks that was sustained through the end of study, and outperformed ritlecitinib.”","length":717,"tagName":"p"},{"type":"text","content":"Continued Dr. Kolbeck, “The murine model of alopecia areata has been well-validated and is highly predictive of clinical responses in human trials of JAK inhibitors, including ritlecitinib. The rapid onset of hair regrowth in mice treated with ATI-2138 is compell...